Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 24:14:17562872221122484.
doi: 10.1177/17562872221122484. eCollection 2022 Jan-Dec.

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data

Elena Andretta  1 , Enrico Finazzi Agrò  2   3 , Massimiliano Calabrese  4 , Luca Orecchia  3 , Antonietta Furlan  5 , Cristina Zuliani  6
Affiliations

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data

Elena Andretta et al. Ther Adv Urol. .

Abstract

Background: Antimuscarinics (AMs) represent the mainstay of treatment for storage lower urinary tract symptoms (LUTS) but few data are available on their impact in multiple sclerosis (MS) patients.

Objective: To assess effectiveness and tolerability of AMs in MS patients with neurogenic detrusor overactivity (NDO).

Methods: Sixty consecutive outpatients, who started treatment with AMs at one centre, were recruited. The primary endpoint was change in Patient's Perception of Intensity of Urgency Scale (PPIUS) at 6 months; secondary endpoints were post-void residual urine (PVR) and pads used daily. Incidence and severity of adverse events (AEs) were recorded.

Results: Significant reduction (p < 0.001) of mean PPIUS and pads use were detected, as well as a significant increase (p < 0.001) of PVR (143 ± 42 ml).AEs, recorded in 53% of patients, were frequently multiple and caused suspension of AM in 10% of cases, mainly for xerostomia, which has been the commonest AE (26.6%). Neurological AEs appeared in 11.7% of subjects, mostly with oxybutynin. Worsening/onset of voiding LUTS, reported by 8.3% of MS, resulted to be the unique AE correlated to AM dosage.

Conclusion: This study suggests that AMs are effective in MS patients, but their use should be tailored on every patient as even low dosages can be poorly tolerated. AEs, including neurological ones, are common.

Keywords: antimuscarinics; lower urinary tract symptoms; multiple sclerosis; neurogenic detrusor overactivity; urgency urinary incontinence.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: EA received honoraria for advisory board commitment, consultancy, as well as conference travel support from Allergan, Coloplast, Wellspect and Teleflex. EFA received honoraria for advisory board commitment from Laborie and consultancy, as well as conference travel support from Recordati and Pierre-Fabre. MC received honoraria for advisory board commitment, consultancy, as well as conference travel support from Merck, Sanofi-Genzyme, Novartis, Biogen and Roche. LO and AF did not declare any competing interests. CZ received honoraria for advisory board commitment, consultancy, as well as conference travel support from Merck, Sanofi-Genzyme, Novartis and Biogen.

Figures

Figure 1.
Figure 1.
Patient’s perception of intensity of urgency scale (PPIUS) changes at 6 months.
Figure 2.
Figure 2.
Post-void residual (PVR) changes at 6 months.
Figure 3.
Figure 3.
Pads use changes at 6 months.
See this image and copyright information in PMC

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502–1517. - PubMed
    1. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61: 288–299. - PubMed
    1. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors: environmental risk factors for MS. Ann Neurol 2007; 61: 504–513. - PubMed
    1. de Sèze M, Ruffion A, Denys P, et al.. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13: 915–928. - PubMed
    1. De Ridder D, Van Der Aa F, Debruyne J, et al.. Consensus guidelines on the neurologist’s role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis. Clin Neurol Neurosurg 2013; 115: 2033–2040. - PubMed